LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 28

Search options

  1. Article ; Online: UDCA in UC: A true disease modifier or symptoms reliever?

    Sulais, Eman Al

    Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

    2021  Volume 27, Issue 4, Page(s) 257

    MeSH term(s) Humans ; Ursodeoxycholic Acid/therapeutic use
    Chemical Substances Ursodeoxycholic Acid (724L30Y2QR)
    Language English
    Publishing date 2021-07-27
    Publishing country India
    Document type Letter ; Comment
    ZDB-ID 2299174-8
    ISSN 1998-4049 ; 1319-3767
    ISSN (online) 1998-4049
    ISSN 1319-3767
    DOI 10.4103/sjg.sjg_228_21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The great wall of inflammatory bowel disease.

    Al Sulais, Eman / Raine, Tim

    Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

    2022  Volume 28, Issue 3, Page(s) 165–167

    MeSH term(s) Crohn Disease ; Humans ; Inflammatory Bowel Diseases/therapy
    Language English
    Publishing date 2022-04-13
    Publishing country India
    Document type Editorial
    ZDB-ID 2299174-8
    ISSN 1998-4049 ; 1319-3767
    ISSN (online) 1998-4049
    ISSN 1319-3767
    DOI 10.4103/sjg.sjg_102_22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Risk of HBV Reactivation Among IBD patients With Occult Hepatitis B Virus Infection.

    Alameel, Turki / Al Sulais, Eman

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

    2020  Volume 19, Issue 3, Page(s) 621–622

    Language English
    Publishing date 2020-11-26
    Publishing country United States
    Document type Letter
    ZDB-ID 2119789-1
    ISSN 1542-7714 ; 1542-3565
    ISSN (online) 1542-7714
    ISSN 1542-3565
    DOI 10.1016/j.cgh.2020.04.089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Methotrexate in inflammatory bowel disease: A primer for gastroenterologists.

    AlAmeel, Turki / Al Sulais, Eman / Raine, Tim

    Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

    2022  Volume 28, Issue 4, Page(s) 250–260

    Abstract: Methotrexate is an antineoplastic agent that is also used at lower doses for anti-inflammatory properties. Along with thiopurines (azathioprine and 6-mercaptopurine), it has historically been an important part of pharmacological treatment for patients ... ...

    Abstract Methotrexate is an antineoplastic agent that is also used at lower doses for anti-inflammatory properties. Along with thiopurines (azathioprine and 6-mercaptopurine), it has historically been an important part of pharmacological treatment for patients with inflammatory bowel disease. Despite an increase in therapeutic options, these immunomodulators continue to play important roles in the management of inflammatory bowel disease, used either as a monotherapy in mild to moderate cases or in combination with monoclonal antibodies to prevent immunogenicity and maintain efficacy. In light of data linking the use of thiopurines with the risk of malignancies, methotrexate has regained attention as a potential alternative. In this article, we review data on the pharmacology, safety, and efficacy of methotrexate and discuss options for the positioning of methotrexate alone, or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.
    MeSH term(s) Azathioprine/therapeutic use ; Colitis, Ulcerative/drug therapy ; Gastroenterologists ; Humans ; Immunosuppressive Agents/therapeutic use ; Inflammatory Bowel Diseases/drug therapy ; Mercaptopurine/therapeutic use ; Methotrexate/therapeutic use
    Chemical Substances Immunosuppressive Agents ; Mercaptopurine (E7WED276I5) ; Azathioprine (MRK240IY2L) ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2022-01-19
    Publishing country India
    Document type Journal Article ; Review
    ZDB-ID 2299174-8
    ISSN 1998-4049 ; 1319-3767
    ISSN (online) 1998-4049
    ISSN 1319-3767
    DOI 10.4103/sjg.sjg_496_21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Is it Time to be Active with Proactive TDM?

    Al Sulais, Eman / AlAmeel, Turki

    Journal of Crohn's & colitis

    2020  Volume 14, Issue 9, Page(s) 1337

    MeSH term(s) Gastrointestinal Agents/therapeutic use ; Humans ; Inflammatory Bowel Diseases/drug therapy
    Chemical Substances Gastrointestinal Agents
    Language English
    Publishing date 2020-02-21
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2390120-2
    ISSN 1876-4479 ; 1873-9946
    ISSN (online) 1876-4479
    ISSN 1873-9946
    DOI 10.1093/ecco-jcc/jjaa034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States.

    Al Sulais, Eman / Alsahafi, Majid / AlAmeel, Turki

    Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

    2021  Volume 27, Issue 6, Page(s) 342–347

    Abstract: Background: Payments from pharmaceutical drug manufacturers to authors of clinical practice guidelines (CPGs) may have an impact on their recommendations. In this study, we aimed to evaluate the accuracy of financial conflict of interest (FCOI) ... ...

    Abstract Background: Payments from pharmaceutical drug manufacturers to authors of clinical practice guidelines (CPGs) may have an impact on their recommendations. In this study, we aimed to evaluate the accuracy of financial conflict of interest (FCOI) declarations among authors of Inflammatory Bowel Disease (IBD) guidelines.
    Methods: We collected data on industry payments to authors of IBD guidelines published by the American Gastroenterology Association (AGA), American College of Gastroenterology (ACG) and American Society of Gastrointestinal Endoscopy (ASGE). We reported the accuracy of the authors' declarations by comparing their statements in the FCOI section of the guidelines with the data reported on the Centers for Medicare and Medicaid Services website (CMS-OP). We also investigated the adherence of IBD guidelines to the National Academy of Medicine (NAM) criteria for trustworthy guidelines.
    Results: A total of eight clinical practice guidelines and 35 individual authors were included. Four authors had no profile identified at CMS-OP. The total payment to all included authors was $10,575,843.06, with a mean payment of $314,242.38 per author. A total of 28/35 authors (80%) received payment from pharmaceutical companies, 23/35 (65.7%) received $10,000 or more, 15/35 (42.8%) received $100,000 or more and 3/35 (8.57%) received $1,000,000 or more. Total discrepancies identified while comparing the authors' declaration of their FCOI and CMS-OP were 28: ACG had 12/14 (85.7%), AGA had 7/12 (53.8%) and ASGE had 9/10 (90%) discrepancies. None of the guidelines met all NAM criteria and 4/8 (50%) guidelines met none.
    Conclusions: Discrepancies exist between authors' declarations in the FOCI section and data on CMS-OP. Poor compliance with the NAM criteria was prevalent among authors of IBD guidelines. More transparency in reporting and monitoring is needed.
    MeSH term(s) Aged ; Authorship ; Disclosure ; Drug Industry ; Humans ; Inflammatory Bowel Diseases/drug therapy ; Medicare ; Pharmaceutical Preparations ; United States
    Chemical Substances Pharmaceutical Preparations
    Language English
    Publishing date 2021-11-03
    Publishing country India
    Document type Journal Article
    ZDB-ID 2299174-8
    ISSN 1998-4049 ; 1319-3767
    ISSN (online) 1998-4049
    ISSN 1319-3767
    DOI 10.4103/sjg.sjg_426_21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Idiopathic Myointimal Hyperplasia of Mesenteric Veins (IMHMV) with two spontaneous bowel perforations: A case report and literature review.

    Almumtin, Ahmed / Al Sulais, Eman / Elhag, Mohammed Atif

    International journal of surgery case reports

    2021  Volume 83, Page(s) 106022

    Abstract: Introduction and importance: Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV) is a poorly understood disorder which poses a diagnostic challenge to clinicians and pathologists. Here we have described the case of a male patient with ... ...

    Abstract Introduction and importance: Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV) is a poorly understood disorder which poses a diagnostic challenge to clinicians and pathologists. Here we have described the case of a male patient with IMHMV along with a presumed history of ulcerative colitis for 1 year.
    Case presentation: A 55-year-old male presented to the OPD with history of chronic abdominal pain. Clinical and radiological examination coupled with endoscopic findings resulted in the patient being wrongly diagnosed to be a case of ulcerative colitis and was managed accordingly. Throughout his multiple hospital visits following treatment for ulcerative colitis, the patient was persistently symptomatic. He presented with 10 days history of increasing abdominal pain and constipation following which he developed spontaneous colonic perforation for which he underwent exploratory laparotomy left colectomy and Hartman's procedure. The final pathology of the resected colon found to be consistent of Idiopathic myointimal hyperplasia of the mesenteric veins and ischemic bowel changes.
    Clinical discussion: The absence of clear-cut endoscopic biopsy findings of ulcerative colitis made radiological picture to be the mainstay for diagnosis, which was inaccurate and exposed the patient to unnecessary treatment with immuno-modulators thus resulting in poor response to treatment. As the disease progressed, further narrowing of the vessels made the clinical picture to look closer to ischemic bowel pathology as the patient developed a top surgical emergency (i.e. bowel perforation). Such pathological finding (IMHMV) can only be diagnosed in a fully prepared tissue histology, but rather be considered when no other consistent alternative diagnosis was found.
    Conclusion: The treating physicians must definitely consider the possibility of idiopathic myointimal hyperplasia of mesenteric veins when similar manifestations are encountered in biopsy specimens of old cases with suspected inflammatory bowel disease or non-occlusive ischemia of the distal colorectum.
    Language English
    Publishing date 2021-05-26
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2210-2612
    ISSN 2210-2612
    DOI 10.1016/j.ijscr.2021.106022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Ustekinumab and Pregnancy: Continue or Cease Before You Conceive?

    AlAmeel, Turki / Al Sulais, Eman

    Gastroenterology

    2019  Volume 157, Issue 5, Page(s) 1435

    MeSH term(s) Female ; Gastroenterology ; Humans ; Inflammatory Bowel Diseases ; Pregnancy ; Psoriasis ; Ustekinumab
    Chemical Substances Ustekinumab (FU77B4U5Z0)
    Language English
    Publishing date 2019-09-09
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2019.05.077
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Family History Is a Risk Factor for Developing Malignancies.

    Al Sulais, Eman / AlAmeel, Turki

    The American journal of gastroenterology

    2019  Volume 114, Issue 8, Page(s) 1346

    MeSH term(s) Cohort Studies ; Humans ; Incidence ; Inflammatory Bowel Diseases ; Neoplasms ; Risk Factors
    Language English
    Publishing date 2019-04-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 390122-1
    ISSN 1572-0241 ; 0002-9270
    ISSN (online) 1572-0241
    ISSN 0002-9270
    DOI 10.14309/ajg.0000000000000251
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease.

    Al Sulais, Eman / AlAmeel, Turki

    Biologics : targets & therapy

    2020  Volume 14, Page(s) 1–11

    Abstract: Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is ... ...

    Abstract Anti- tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of these agents is the high cost. The introduction of biosimilar products to anti-TNF agents is expected to lower the cost. Health care providers ought to be aware of the available data that addresses the safety and efficacy of biosimilars in IBD patients. This article outlines the current evidence-based data regarding the available biosimilar products, their safety, efficacy and how to deal with patients' concerns.
    Language English
    Publishing date 2020-01-10
    Publishing country New Zealand
    Document type Journal Article ; Review
    ISSN 1177-5475
    ISSN 1177-5475
    DOI 10.2147/BTT.S236433
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top